Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.
Bansi, L.
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. - 2010
NMUH Staff Publications 11
<span style="font-size: 8pt;"><br /></span><div style="line-height: 17.999801635742188px;"><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">OBJECTIVE:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">Effective <span class="highlight">antiretroviral</span> therapy (ART) has transformed the care of people with <span class="highlight">HIV</span>, but it is important to monitor <span class="highlight">time</span> <span class="highlight">trends</span> in indicators of <span class="highlight">treatment</span> <span class="highlight">success</span> and antic future changes.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">METHODS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">We assessed <span class="highlight">time</span> <span class="highlight">trends</span> from 2000 to 2007 in several indicators of <span class="highlight">treatment</span> <span class="highlight">success</span> in the UK Collaborative <span class="highlight">HIV</span> Cohort (CHIC) Study, and using national <span class="highlight">HIV</span> data from the Health Protection Agency (HPA) we developed a model to project future <span class="highlight">trends</span>.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">RESULTS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">The proportion of patients on ART with a viral load <50 <span class="highlight">HIV</span>-1 RNA copies/mL increased from 62% in 2000 to 84% in 2007, and the proportion of all patients with a CD4 count <200 cells/microL decreased from 21% to 10%. During this period, the number of patients who experienced extensive triple class <span class="highlight">failure</span> (ETCF) rose from 147 (0.9%) to 1771 (3.9%). The number who experienced such ETCF and had a current viral load >50 copies/mL rose fromz 118 (0.7%) to 857 (1.9%). Projections to 2012 suggest sustained high levels of <span class="highlight">success</span>, with a continued increase in the number of patients who have failed multiple drugs but a relatively stable number of such patients experiencing viral loads >50 copies/mL. Numbers of deaths are projected to remain low.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">CONCLUSIONS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">There have been continued improvements in key indicators of <span class="highlight">success</span> in patients with <span class="highlight">HIV</span> from 2000 to 2007. Although the number of patients who have ETCF is projected to rise in the future, the number of such patients with viral loads >50 copies/mL is not projected to increase up to 2012. New drugs may be needed in future to sustain these positive <span class="highlight">trends</span>.</span></p></div>
14642662
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. - 2010
NMUH Staff Publications 11
<span style="font-size: 8pt;"><br /></span><div style="line-height: 17.999801635742188px;"><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">OBJECTIVE:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">Effective <span class="highlight">antiretroviral</span> therapy (ART) has transformed the care of people with <span class="highlight">HIV</span>, but it is important to monitor <span class="highlight">time</span> <span class="highlight">trends</span> in indicators of <span class="highlight">treatment</span> <span class="highlight">success</span> and antic future changes.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">METHODS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">We assessed <span class="highlight">time</span> <span class="highlight">trends</span> from 2000 to 2007 in several indicators of <span class="highlight">treatment</span> <span class="highlight">success</span> in the UK Collaborative <span class="highlight">HIV</span> Cohort (CHIC) Study, and using national <span class="highlight">HIV</span> data from the Health Protection Agency (HPA) we developed a model to project future <span class="highlight">trends</span>.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">RESULTS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">The proportion of patients on ART with a viral load <50 <span class="highlight">HIV</span>-1 RNA copies/mL increased from 62% in 2000 to 84% in 2007, and the proportion of all patients with a CD4 count <200 cells/microL decreased from 21% to 10%. During this period, the number of patients who experienced extensive triple class <span class="highlight">failure</span> (ETCF) rose from 147 (0.9%) to 1771 (3.9%). The number who experienced such ETCF and had a current viral load >50 copies/mL rose fromz 118 (0.7%) to 857 (1.9%). Projections to 2012 suggest sustained high levels of <span class="highlight">success</span>, with a continued increase in the number of patients who have failed multiple drugs but a relatively stable number of such patients experiencing viral loads >50 copies/mL. Numbers of deaths are projected to remain low.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">CONCLUSIONS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">There have been continued improvements in key indicators of <span class="highlight">success</span> in patients with <span class="highlight">HIV</span> from 2000 to 2007. Although the number of patients who have ETCF is projected to rise in the future, the number of such patients with viral loads >50 copies/mL is not projected to increase up to 2012. New drugs may be needed in future to sustain these positive <span class="highlight">trends</span>.</span></p></div>
14642662